Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Repaglinide + NPH vs NPH in T2D
NCT01562561Phase 3Completed
- Sponsor
- Novo Nordisk
- Start
- Jun 2001
- Primary completion
- Dec 2002
- Modality
- Small Molecules
- Countries
- 5
01
Overview
Phase 3, randomised, open-label trial of repaglinide in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Novo Nordisk. Primary endpoint: Glycosylated Haemoglobin at 26 weeks. Started Jun 2001; status: completed.
02
Drugs
repaglinide
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT01562561.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01562561.